Whole genome sequencing to identify predictive markers for the risk of drug-induced interstitial lung disease

PLoS One. 2019 Oct 4;14(10):e0223371. doi: 10.1371/journal.pone.0223371. eCollection 2019.

Abstract

Drug-induced interstitial lung disease (DIILD) is a serious side effect of chemotherapy in cancer patients with an extremely high mortality rate. In this study, to identify genetic variants with greater risk of DIILD, we carried out whole genome sequencing (WGS) of germline DNA samples from 26 patients who developed DIILD, and conducted a case-control association study between these 26 cases and general Japanese population controls registered in the integrative Japanese Genome Variation Database (iJGVD) as a screening study. The associations of 42 single nucleotide variants (SNVs) showing P < 0.0001 were further validated using an independent cohort of 18 DIILD cases as a replication study. A further combined analysis of the screening and replication studies showed a possible association of two SNVs, rs35198919 in intron 1 of the chromosome 22 open reading frame 34 (C22orf34) and rs12625311 in intron 1 of the teashirt zinc finger homeobox 2 (TSHZ2), with DIILD (Pcombined = 1.87 × 10-5 and 5.16 × 10-5, respectively). Furthermore, in a subgroup analysis of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI)-induced interstitial lung disease (ILD), we observed seven candidate SNVs that were possibly associated with ILD (P < 0.00001). This is the first study to identify genetic markers for the risk of DIILD using WGS. Collectively, our novel findings indicate that these SNVs may be applicable for predicting the risk of DIILD in patients receiving chemotherapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Biomarkers*
  • Case-Control Studies
  • Female
  • Genetic Predisposition to Disease*
  • Humans
  • Lung Diseases, Interstitial / diagnosis*
  • Lung Diseases, Interstitial / etiology*
  • Male
  • Middle Aged
  • Mutation
  • Neoplasms / complications*
  • Neoplasms / drug therapy
  • Polymorphism, Single Nucleotide
  • Prognosis
  • Protein Kinase Inhibitors / adverse effects
  • Protein Kinase Inhibitors / therapeutic use
  • Whole Genome Sequencing

Substances

  • Biomarkers
  • Protein Kinase Inhibitors

Grants and funding

This work was supported by AstraZeneca (HZ), https://www.astrazeneca.com/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.